Literature DB >> 9607048

Circulating antibody secreting cell response to parenteral pneumococcal vaccines as an indicator of a salivary IgA antibody response.

T Nieminen1, H Käyhty, A Virolainen, J Eskola.   

Abstract

This study assessed the mucosal immune response in healthy adult volunteers immunized parenterally with either pneumococcal polysaccharide (N = 8) or pneumococcal polysaccharide-protein conjugate (N = 10) vaccine with an aim to evaluate the relevance of antibody secreting cell (ASC) response after parenteral vaccination. An ASC response to the four types of capsular polysaccharide tested was observed in all vaccinees 7-9 days after immunization. IgA was the predominant class in the ASC response, and IgG the next common, with very few IgM ASCs. The IgA/IgG ratio in the ASC response was higher after immunization with the polysaccharide than the conjugate vaccine. Antibodies of the IgA class were frequently seen in the saliva already before immunization; especially to serotypes 14 and 19F. A twofold increase of the type specific secretory IgA antibodies in saliva was found in eight of the 16 instances in which the specific IgA ASC response was > 100 ASC per 10(6) cells and in only one of the 52 instances with fewer ASCs. We conclude that the ASC response in the peripheral blood is a useful parameter of the antibody response to pneumococcal vaccines and a good indicator of a secretory IgA response in the saliva.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607048     DOI: 10.1016/s0264-410x(97)00162-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  B and T cell immunity in patients with lysinuric protein intolerance.

Authors:  M Lukkarinen; K Parto; O Ruuskanen; O Vainio; H Käyhty; R M Olander; O Simell
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

Review 2.  Evaluation of events occurring at mucosal surfaces: techniques used to collect and analyze mucosal secretions and cells.

Authors:  Bruno Guy
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

3.  Immune profile of asplenic patients following single or double vaccine administration: A longitudinal cross-sectional study.

Authors:  Sait Murat Doğan; Ahmet Aykas; Evrim Şefika Yücel; Gökalp Okut; Cenk Şimşek; Kürşat Çayhan; Baha Zengel; Adam Uslu
Journal:  Ulus Cerrahi Derg       Date:  2015-04-09

4.  The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine.

Authors:  Elizabeth A Clutterbuck; Penny Salt; Sarah Oh; Arnaud Marchant; Peter Beverley; Andrew John Pollard
Journal:  Immunology       Date:  2006-11       Impact factor: 7.397

Review 5.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

6.  Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans.

Authors:  Geraldine Blanchard-Rohner; Anoop S Pulickal; Cornelia M Jol-van der Zijde; Matthew D Snape; Andrew J Pollard
Journal:  Blood       Date:  2009-10-20       Impact factor: 22.113

7.  Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis.

Authors:  Kenneth Smith; Jennifer J Muther; Angie L Duke; Emily McKee; Nai-Ying Zheng; Patrick C Wilson; Judith A James
Journal:  Immunobiology       Date:  2012-09-03       Impact factor: 3.144

8.  Salivary antibodies induced by the seven-valent PncOMPC conjugate vaccine in the Finnish Otitis Media Vaccine Trial.

Authors:  Anu Nurkka; Mika Lahdenkari; Arto A I Palmu; Helena Käyhty
Journal:  BMC Infect Dis       Date:  2005-05-27       Impact factor: 3.090

Review 9.  Hib Vaccines: Past, Present, and Future Perspectives.

Authors:  Adi Essam Zarei; Hussein A Almehdar; Elrashdy M Redwan
Journal:  J Immunol Res       Date:  2016-01-20       Impact factor: 4.818

10.  Different Dynamics for IgG and IgA Memory B Cells in Adolescents following a Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster Vaccination Nine Years after Priming: A Role for Priming Age?

Authors:  Susanne P Stoof; Anne-Marie Buisman; Debbie M van Rooijen; Rianne Boonacker; Fiona R M van der Klis; Elisabeth A M Sanders; Guy A M Berbers
Journal:  PLoS One       Date:  2015-10-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.